Boxer Capital Management LLC Has $18.06 Million Stock Holdings in Kymera Therapeutics, Inc. $KYMR

Boxer Capital Management LLC lessened its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 26.1% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 319,100 shares of the company’s stock after selling 112,910 shares during the quarter. Kymera Therapeutics makes up 5.8% of Boxer Capital Management LLC’s portfolio, making the stock its 4th biggest position. Boxer Capital Management LLC’s holdings in Kymera Therapeutics were worth $18,061,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KYMR. PNC Financial Services Group Inc. grew its stake in Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares during the period. Osaic Holdings Inc. lifted its holdings in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Kymera Therapeutics in the 2nd quarter valued at approximately $73,000. Finally, US Bancorp DE increased its stake in Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after purchasing an additional 166 shares in the last quarter.

Kymera Therapeutics Stock Up 2.0%

Shares of KYMR opened at $79.03 on Friday. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00. The stock has a market capitalization of $6.45 billion, a P/E ratio of -21.48 and a beta of 2.20. The company has a 50 day moving average of $79.21 and a 200-day moving average of $68.32.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. During the same period in the prior year, the firm earned ($0.88) EPS. The business’s revenue for the quarter was down 60.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Leerink Partners increased their price objective on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Citigroup raised their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Stifel Nicolaus set a $114.00 price objective on shares of Kymera Therapeutics in a research report on Monday, December 8th. Finally, B. Riley Financial upped their target price on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Insider Transactions at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00. Following the completion of the transaction, the chief executive officer owned 666,195 shares in the company, valued at $60,130,760.70. This trade represents a 4.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bruce Booth sold 81,866 shares of Kymera Therapeutics stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $90.13, for a total value of $7,378,582.58. Following the completion of the sale, the director directly owned 675,341 shares in the company, valued at approximately $60,868,484.33. This represents a 10.81% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 196,561 shares of company stock worth $17,097,428. 16.01% of the stock is owned by insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.